Human fungal pathogens exemplify a severe threat to health due to their complex infection strategies and the host's immune system's failure to eradicate ...

Recent research has focused on understanding the biosynthesis of these antifungal compounds, their mechanisms of action, and how they can be effectively utilized in treating fungal infections.

Another issue is that antifungal drug development takes a long ... Over the last 25 years, a compound with a novel mechanism ...

An often-overlooked mechanism of gene regulation may be involved in the failure of antifungal drugs in the clinic, claims a German-Austrian research team led by the Leibniz Institute for Natural ...

Another issue is that antifungal drug development takes a long ... Over the last 25 years, a compound with a novel mechanism of action has been in development called olorofim.

Cutaneous fungal infections that generally require systemic antifungal therapy include tinea capitis and onychomycosis. Tinea capitis, which is most often caused by Trichophyton tonsurans ...

"For decades, clinicians have relied on a handful of antifungal classes, with few mechanisms of action and significant limitations due to spectrum of activity, drug toxicities, or drug-drug ...

These methods have been adopted as part of the CLSI Reference Methods for Antifungal Susceptibility Testing. Strong support for these research efforts are drawn from different sources including the ...

Olorofim (F901318) is the first in a new class of orotomide antifungal agents intended ... dihydroorotate dehydrogenase (DHODH), a different mechanism from that of the currently marketed therapies ...

See the article: Improving the production of micafungin precursor FR901379 in Coleophoma empetri using heavy-ion irradiation and its mechanism analysis ...